


The rewritten claim 6 without marking under 37 CFR 1.121 (c) (1) (i).

6(amended). A compound of Claim 1 wherein m is 1 and n is 2.

A clean version of the entire set of pending claims under 37 CFR 1.121 (c) (3).

1(amended). A compound of Formula I:



(I)

or pharmaceutical acceptable salts thereof wherein:

X is NR₁;

R₁ is

- H,
- C₁₋₆ alkyl, optionally substituted with one or more OH, CN, or halo,
- (CH₂)_h-aryl,
- COR₁₋₁,
- COOR₁₋₂,
- CO-(CH₂)_h-COR₁₋₁,
- SO₂-C₁₋₆ alkyl,
- SO₂-(CH₂)_h-aryl, or
- (CO)_i-Het;

R₁₋₁ is

- H,
- C₁₋₆ alkyl, optionally substituted with one or more OH, CN, or halo,
- (CH₂)_h-aryl, or
- (CH₂)_h-OR₁₋₃;

R₁₋₂ is

- a) C₁₋₆ alkyl, optionally substituted with one or more OH, CN, or halo,
- b) -(CH₂)_h-aryl, or
- c) -(CH₂)_h-OR₁₋₃;

R₁₋₃ is

- a) H,
- b) C₁₋₆ alkyl,
- c) -(CH₂)_h-aryl, or
- d) -CO(C₁₋₆ alkyl);

R₂ is

- a) H,
- b) C₁₋₆ alkyl,
- c) -(CH₂)_h-aryl, or
- d) halo;

R₃ and R₄ are independently

- a) H, or
- b) halo;

R₅ is

- a) H,
- b) C₁₋₁₂ alkyl, optionally substituted with one or more halo,
- c) C₃₋₁₂ cycloalkyl,
- d) C₁₋₆ alkoxy;

Het is 5- to 10-membered heterocyclic rings having one or more oxygen, nitrogen, and sulfur atoms;

the dotted line ----- in the ring system of Formula I is a single or a double bond;

h is 1, 2, 3, or 4;

i is 0 or 1;

m is 0, 1, 2, 3, 4, or 5;

n is 0, 1, 2, 3, 4, or 5;

and with the following provisos:

- a) m and n taken together are 3;
- b) where the dotted line ----- is a double bond, R₂ is not present in Fomula I.

2. A compound of Claim 1 wherein R₁ is selected from the group consisting of H, fluoroethyl, cyanomethyl, methyl sulfonyl, formyl, hydroxyacetyl, acetyl, methoxyacetyl, benzyloxyacetyl, acetoxyacetyl, dichloroacetyl, methoxy carbonyl, tert-butoxy carbonyl, benzyloxy carbonyl, 3-hydroxypropionyl, 3-methoxypropionyl, 4-oxopentanoyl, 2-indole carbonyl, 5-isoxazole carbonyl, 5-nitro-2-thiazoyl, 4-oxo-2-thiazolinyl, and 5-methyl-1,3,4-thiadiazol-2-yl.

3. A compound of Claim 1 wherein R₂ is H, F, or CH₃.

4. A compound of Claim 1 wherein R₃ and R₄ are independently H or F.

5. A compound of Claim 1 wherein R₅ is methyl, ethyl, cyclopropyl, or methyl substituted with one to two F or Cl.

6(amended). A compound of Claim 1 wherein m is 1 and n is 2.

8. A compound of Claim 1 which is an optically pure enantiomer having the S-configuration at C5 of the oxazolidinone ring.

11. A method for treating microbial infections in patients comprising:
administering to a patient in need thereof an effective amount of a compound of Formula I as shown in Claim 1.

12. The method of Claim 11 wherein said compound of Formula I is administered orally, parenterally or topically in a pharmaceutical composition.
13. The method of Claim 11 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.
- 14(new). A compound selected from the group consisting of:
- a) (S)-(-)-4-[4-[5-[(Acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinecarboxylic acid phenylmethyl ester;
 - b) (S)-(-)-N-[[2-Oxo-3-[4-(4-piperidinyl)phenyl]-5-oxazolidinyl]methyl]acetamide;
 - c) (S)-(-)-N-[[3-[4-[1-[(Benzyloxy)acetyl]-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
 - d) (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
 - e) (S)-(-)-N-[[3-[4-[1-[(Benzyloxy)acetyl]-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
 - f) (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
 - g) (S)-(-)-N-[[3-[4-[1-[(Benzyloxy)acetyl]-4-piperidinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
 - h) (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-4-piperidinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
 - i) (S)-(-)-N-[[3-[4-[1-(Indole-2-carbonyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
 - j) (S)-(-)-N-[[3-[4-[1-(Isoxazole-5-carbonyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
 - k) (S)-(-)-N-[[3-[4-[1-(Methylsulfonyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
 - l) (S)-(-)-4-[4-[5-[(Acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperidinecarboxylic acid methyl ester;

- m) (S)-(-)-N-[[3-[4-[1-(Cyanomethyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- n) (S)-(-)-N-[[3-[4-[1-(2-Fluoroethyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- o) (S)-(-)-N-[[3-[4-[1-(Formyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- p) (S)-(-)-4-[4-[5-[[2,2-Dichloroacetyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester;
- q) (S)-(-)-2,2-Dichloro-N-[[2-oxo-3-[3-fluoro-4-(4-piperidinyl)phenyl]-5-oxazolidinyl]methyl]acetamide;
- r) (S)-(-)-2,2-Dichloro-N-[[2-oxo-3-[3-fluoro-4-[1-[(acetoxyl)acetyl]-4-piperidinyl]phenyl]-5-oxazolidinyl]methyl]acetamide;
- s) (S)-(-)-2,2-Dichloro-N-[[2-oxo-3-[3-fluoro-4-[1-(hydroxyacetyl)-4-piperidinyl]phenyl]-5-oxazolidinyl]methyl]acetamide;
- t) (S)-(-)-N-[[2-Oxo-3-[3-fluoro-4-[1-[(acetoxyl)acetyl]-4-piperidinyl]phenyl]-5-oxazolidinyl]methyl]acetamide;
- u) (S)-(-)-N-[[3-[4-[1-(4-Oxo-2-thiazolanyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- v) (S)-(-)-N-[[3-[4-[1-(4-Oxo-2-thiazolanyl)-3,6-dihydro-2H-pyridin-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- w) (S)-(-)-N-[[3-[4-[1-(5-Methyl-1,3,4-thiadiazol-2-yl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- x) (S)-(-)-N-[[3-[4-[1-(5-Methyl-1,3,4-thiadiazol-2-yl)-3,6-dihydro-2H-pyridin-4-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- y) (S)-(-)-N-[[2-Oxo-3-[4-(3,6-dihydro-2H-pyridin-4-yl)-3-fluorophenyl]-5-oxazolidinyl]methyl]acetamide;
- z) (S)-(-)-N-[[2-Oxo-3-[3-fluoro-4-[1-[(acetoxyl)acetyl]-3,6-dihydro-2H-pyridin-4-yl]phenyl]-5-oxazolidinyl]methyl]acetamide;
- aa) (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-3,6-dihydro-2H-pyridin-4-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

- bb) (S)-(-)-N-[[3-[4-[1-(Formyl)-3,6-dihydro-2H-pyridin-4-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- cc) (S)-(-)-4-[4-[5-[(Acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3,6-dihydro-1(2H)-pyridinecarboxylic acid methyl ester;
- dd) (S)-(-)-N-[[2-Oxo-3-[4-(3,6-dihydro-2H-pyridin-4-yl)phenyl]-5-oxazolidinyl]methyl]acetamide;
- ee) (S)-(-)-N-[[2-Oxo-3-[4-[1-[(acetoxy)acetyl]-3,6-dihydro-2H-pyridin-4-yl]phenyl]-5-oxazolidinyl]methyl]acetamide;
- ff) (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-3,6-dihydro-2H-pyridin-4-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- gg) (S)-(-)-N-[[3-[4-[1-(Formyl)-3,6-dihydro-2H-pyridin-4-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- hh) (S)-(-)-4-[4-[5-[(Acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinecarboxylic acid methyl ester;
- ii) (S)-N-[[2-Oxo-3-[3-fluoro-4-[1-[(acetoxy)acetyl]-5,6-dihydro-2H-pyridin-3-yl]phenyl]-5-oxazolidinyl]methyl]acetamide;
- jj) (S)-N-[[3-[4-[1-(Hydroxyacetyl)-5,6-dihydro-2H-pyridin-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- kk) (S)-N-[[2-Oxo-3-[3-fluoro-4-[1-[(acetoxy)acetyl]-3,4-dihydro-2H-pyridin-5-yl]phenyl]-5-oxazolidinyl]methyl]acetamide;
- ll) (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-3,4-dihydro-2H-pyridin-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; and
- mm) (S)-(-)-N-[[3-[4-[1-Formyl-4-fluoro-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

15(new). A compound of Claim 14 which is:

- a) (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- b) (S)-(-)-N-[[3-[4-[1-(Formyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;

- c) (S)-(-)-2,2-Dichloro-N-[[2-oxo-3-[3-fluoro-4-[1-(hydroxyacetyl)-4-piperidinyl]phenyl]-5-oxazolidinyl]methyl]acetamide;
- d) (S)-(-)-N-[[2-Oxo-3-[3-fluoro-4-[1-[(acetoxycetyl)-3,6-dihydro-2H-pyridin-4-yl]phenyl]-5-oxazolidinyl]methyl]acetamide;
- e) (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-3,6-dihydro-2H-pyridin-4-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- f) (S)-(-)-N-[[3-[4-[1-(4-Oxo-2-thiazolinyl)-3,6-dihydro-2H-pyridin-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; or
- g) (S)-(-)-N-[[3-[4-[1-(5-Methyl-1,3,4-thiadiazol-2-yl)-3,6-dihydro-2H-pyridin-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

16(new). A compound of claim 1 wherein

R₁ is

- a) C₁₋₆ alkyl, optionally substituted with more than one OH, CN, or fluoro, or one or more chloro, bromo, or iodo,
- b) -(CH₂)_h-aryl,
- c) -COR₁₋₁,
- d) -COOR₁₋₂, or
- e) -CO-(CH₂)_h-COR₁₋₁;

R₁₋₁ is C₁₋₆ alkyl substituted with one or more OH;

R₁₋₂ is

- a) -(CH₂)_h-aryl, or
- b) -(CH₂)_h-OR₁₋₃;

R₁₋₃ is

- a) H,
- b) C₁₋₆ alkyl, or
- c) -(CH₂)_h-aryl;

R₂ is halo;

and h is 1, 2, 3, or 4.

17(new). A compound of claim 16 which is

- a) (S)-(-)-N-[[3-[4-[1-[(benzyloxy)acetyl]-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- b) (S)-(-)-N-[[3-[4-[1-(hydroxyacetyl)-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- c) (S)-(-)-N-[[3-[4-[1-[(benzyloxy)acetyl]-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- d) (S)-(-)-N-[[3-[4-[1-(hydroxyacetyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- e) (S)-(-)-2,2-dichloro-N-[[2-oxo-3-[3-fluoro-4-[1-(hydroxyacetyl)-4-piperidinyl]phenyl]-5-oxazolidinyl]methyl]acetamide,
- f) (S)-(-)-N-[[3-[4-[1-[(benzyloxy)acetyl]-4-piperidinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- g) (S)-(-)-N-[[3-[4-[1-(hydroxyacetyl)-3,6-dihydro-2H-pyridin-4-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- h) (S)-(-)-N-[[3-[4-[1-(hydroxyacetyl)-3,6-dihydro-2H-pyridin-4-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, or
- i) (S)-(-)-N-[[3-[4-[1-formyl-4-fluoro-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

18(new). A compound of claim 1 wherein m is 0 and n is 3; m is 1 and n is 2; or m is 3 and n is 0.

19(new). A compound of claim 18 which is

- a) (S)-(-)-N-[[3-[4-[1-(4-oxo-2-thiazolinyl)-3,6-dihydro-2H-pyridin-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- b) (S)-N-[[2-oxo-3-[3-fluoro-4-[1-[(acetoxo)acetyl]-5,6-dihydro-2H-pyridin-3-yl]phenyl]-5-oxazolidinyl]methyl]acetamide;

- c) (S)-N-[[3-[4-[1-(hydroxyacetyl)-5,6-dihydro-2H-pyridin-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
- d) (S)-N-[[2-oxo-3-[3-fluoro-4-[1-[(acetoxyl)acetyl]-3,4-dihydro-2H-pyridin-5-yl]phenyl]-5-oxazolidinyl]methyl]acetamide; or
- e) (S)-(-)-N-[[3-[4-[1-(hydroxyacetyl)-3,4-dihydro-2H-pyridin-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

20(new). A compound of claim 1 wherein R₂ is C₁₋₆ alkyl, -(CH₂)_n-aryl or halo-